Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Payables (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Payables for 7 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • Quarterly Payables fell 32.96% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, down 32.96% year-over-year, with the annual reading at $4.0 million for FY2025, 32.96% down from the prior year.
  • Payables for Q4 2025 was $4.0 million at Kymera Therapeutics, down from $5.5 million in the prior quarter.
  • The five-year high for Payables was $10.3 million in Q1 2025, with the low at $2.4 million in Q2 2022.
  • Average Payables over 5 years is $5.7 million, with a median of $5.9 million recorded in 2024.
  • The sharpest move saw Payables crashed 70.97% in 2022, then skyrocketed 152.55% in 2023.
  • Over 5 years, Payables stood at $4.0 million in 2021, then increased by 8.24% to $4.3 million in 2022, then surged by 63.21% to $7.1 million in 2023, then decreased by 15.35% to $6.0 million in 2024, then tumbled by 32.96% to $4.0 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $4.0 million, $5.5 million, and $5.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.